283 related articles for article (PubMed ID: 18839855)
1. The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
Kongsakon R; Bunchapattanasakda C
J Med Assoc Thai; 2008 Jul; 91(7):1117-28. PubMed ID: 18839855
[TBL] [Abstract][Full Text] [Related]
2. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
6. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
Malone DC
J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
[TBL] [Abstract][Full Text] [Related]
7. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on the pharmacoeconomics of escitalopram in depression.
Croom KF; Plosker GL
CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
12. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Wade AG; Toumi I; Hemels ME
Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
[TBL] [Abstract][Full Text] [Related]
13. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
[TBL] [Abstract][Full Text] [Related]
14. Escitalopram versus venlafaxine XR in the treatment of depression.
Montgomery SA; Andersen HF
Int Clin Psychopharmacol; 2006 Sep; 21(5):297-309. PubMed ID: 16877901
[TBL] [Abstract][Full Text] [Related]
15. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
Wade AG; Toumi I; Hemels ME
Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G; Danchenko N; Despiegel N; Marteau F
Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
Fernandez JL; Montgomery S; Francois C
Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
19. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]